Metastatic Soft Tissue Sarcoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
ImmunityBioINNO-206
AdcendoAntibody-drug conjugate
Clinical Trials (2)
Total enrollment: 126 patients across 2 trials
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Start: Jan 2012Est. completion: Dec 2014126 patients
Phase 2Completed
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Start: Jun 2025Est. completion: Feb 2029
Phase 1/2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
2h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
2h ago
Office Administrator
SystImmune
2h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 126 patients
ADC is the dominant modality (100% of programs)
2 companies competing in this space